Psoriasis Redefined Webinar Series

The next innovation in skin has arrived.

A series of three CPD certified modules, presented by recognised experts in clinical psoriasis to support you should you decide to use BIMZELX® ▼ (bimekizumab) for treating your eligible adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Off

The BIMZELX®  Difference

paragraph-section-webinars

Psoriasis Redefined webinar 1

The BIMZELX®  Difference
Learn & discover
Describe the importance of both IL-17F and IL-17A in the pathogenesis of psoriasis
Explain how dual-inhibition of IL-17F and IL-17A with BIMZELX® affects both IL-17 and IL-23 pro-inflammatory pathways in psoriasis
Recall key data on efficacy, durability and tolerability from the extensive BIMZELX® clinical trial programme in patients with plaque psoriasis
Recognise the BIMZELX® enhanced Patient Support Programme
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Stevan Shaw (UCB)
  • Dr Kave Shams
  • Lucy Moorhead
Keep track of your progress
Download your Reflective Learning Guide
Duration
39:19 minutes
Date of preparation: October 2021 | GB-P-BK-PSO-2100109

Click here to complete the Evaluation Form

On

The BIMZELX®  Experience

paragraph-section-webinars

Psoriasis Redefined webinar 2

The BIMZELX®  Experience
Learn & discover
Understand the unmet needs of patients with psoriasis
Identify which patient characteristics may benefit from BIMZELX®  and why
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Professor Anthony Bewley
  • Dr Amy Foulkes
Keep track of your progress
Download your Reflective Learning Guide
Duration
33:05 minutes
Date of preparation: October 2021 | GB-P-BK-PSO-2100112

Click here to complete the Evaluation Form

On

BIMZELX®  In Practice

Psoriasis Redefined webinar 3

BIMZELX®  In Practice
Learn & discover
The clinical experience of patients treated with BIMZELX®
Ways in which you can optimise BIMZELX®  patient experience
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Dr Laura Savage
  • Lucy Moorhead
Keep track of your progress
Download your Reflective Learning Guide
Duration
29:58 minutes
Date of preparation: November 2021 | GB-P-BK-PSO-2100166

Click here to complete the Evaluation Form

On
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Click here for Prescribing Information

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: October 2021
GB-P-BK-PSO-2100108